Enanta Pharmaceuticals, Inc.
ENTAHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. With a market capitalization of $410.1M, it sits in small-cap territory. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Market Cap
$410.1M
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-5.57
EPS (TTM)
$-2.42
EPS (Fwd)
$-2.53
ROE
-70.1%
ROA
-12.3%
Cash
$189.5M
Total Debt
$182.0M
Free CF
-$22.7M
52W Change
55.8%
Annual Financials
Cash vs Debt
Where ENTA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ENTA finished 4.60% above its 150-day moving average ($13.47) and 3.68% above its 200-day moving average ($13.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENTA overbought or oversold?
At the September 3, 2026 close, ENTA's RSI(14) was 57.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Enanta Pharmaceuticals, Inc. holds $189.5M in cash against $182.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$22.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -70.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $86.2M (2022) to $65.3M (2025), a 24% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Enanta Pharmaceuticals, Inc.'s trajectory.